                         SEQUENCE LISTING

<110>  Regeneron Pharmaceuticals, Inc.
 
<120>  THERAPEUTIC PROTEIN SELECTION IN SIMULATED IN VIVO CONDITIONS

<130>  10470WO01

<150>  62/718,307
<151>  2018-08-13

<150>  62/865,446
<151>  2019-06-24

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  50
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Partial Peptide Sequence of Wild-Type IgG1 or IgG4

<400>  1

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
1               5                   10                  15      


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            20                  25                  30          


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        35                  40                  45              


Thr Lys 
    50  


<210>  2
<211>  50
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Partial Peptide Sequence of IgG1 or IgG4 with YTE Mutation

<400>  2

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu 
1               5                   10                  15      


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            20                  25                  30          


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        35                  40                  45              


Thr Lys 
    50  


